Astellas announced the expansion of its top Management to include Astellas US President Percival Barretto-Ko was promoted to Chief Business Officer, focused on leading the company's new corporate strategic plan and enhancing Astellas' external and internal innovation. Astellas Institute for Regenerative Medicine President Yoshitsugu Shitaka was promoted to Chief Scientific Officer, with responsibility for operations and the expansion of Astellas' drug discovery research program platforms. He will also serve as Astellas' President of its Drug Discovery Research (DDR) organization. In Barretto-Ko's new role, he will oversee Business Development, Advanced Informatics & Analytics, Intellectual Property: Innovation and New Technologies, Patient Centricity, Information Systems, iota Biosciences, Rx+ Business Accelerator, and a newly established Transformation Office, that will drive the execution of Astellas' new Corporate Strategic Plan. Barretto-Ko has been President of Astellas US since 2018. During his tenure, the US organization achieved record-breaking performance for three consecutive years with double-digit annual growth. Mark Reisenauer will succeed Barretto-Ko as PresidenAstellas Institute for Regenerative Medicine t, US. Reisenauer was previously Senior Vice President, Oncology business unit. In his new role, Reisenauer will be responsible for the operations for Astellas Pharma across the US and report to Chief Commercial OfficerYukio Matsui. Since joining Astellas in 2011 as Vice President of Oncology Sales and Marketing, Reisenauer's leadership has yielded the fastest-growing franchise in Astellas' US portfolio. During his tenure, Astellas' oncology sales grew from less than 10 percent of sales to approximately 50 percent of US sales, and ultimately led to EvaluatePharma citing Astellas as an oncology company to watch – anticipating being in the top 10 of all oncology companies by 2024. Prior to joining Astellas, Reisenauer held various leadership positions at AstraZeneca, Bristol Myers Squibb, Pharmacia, Abbott and Micromet. As a part of these transitions within Astellas US, Senior Vice President of US Medical Specialties Steve Sabus was appointed as Senior Vice President of the Oncology business; Senior Vice President of Health Systems Shontelle Dodson was appointed as Senior Vice President of the Medical Specialties business unit. Masahide Goto will succeed Shitaka as President, Astellas Institute for Regenerative Medicine (AIRM). Headquartered in Westborough, Mass., AIRM is an indirect, wholly owned subsidiary of Astellas and serves as the Company's global hub for regenerative medicine and cell therapy research and manufacturing in ophthalmology and other therapeutic areas that have few or no available treatment options. Goto will report to Shitaka in this new role.